Fresh analysis reveals that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end traditional lifestyle regimens.
Published data in a prominent health publication shows that while overweight people often shed about a fifth of their body weight while on the medication, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"People buying such treatments must be cognizant of the risk of quick rebound weight gain when the medication is stopped," stated expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment weight in about 18 months.
Analyzing Therapies
The analysis, which examined dozens of trials involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with other pills.
Researchers point out that individuals who lose weight through dieting usually have a less rapid creep back—around 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Experts suggest the mechanism of the jabs is key to understanding the accelerated weight return.
These medications copy a natural hormone called GLP-1, which controls hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' means hunger is uncontrolled, making overeating a significant risk."
A Chronic Disease?
The NHS advise the injections for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, considering the significant potential of weight regain, the therapy should be considered long-term.
This view is supported by drug manufacturers, who note that the findings "underscore the persistent nature of excess weight," similar to managing conditions like hypertension.
User Testimonies
Individuals who have discontinued the jabs explain a sudden return of hunger.
"I experienced something activating and you're instantly starving," said one woman.
This difficulty is exacerbated if users have not established permanent dietary or behavioural modifications during treatment.
Significant Adoption
Figures suggest that a significant number of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Use is greater among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Finally, researchers emphasize that while the jabs are effective agents for weight loss, they are not a permanent cure and lasting health benefits relies on integrated behavioural support.
